News & Updates

Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.

In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.

Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.

Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.

Twice-daily application of the botanical coacillium 22.25% cutaneous solution leads to significant hair growth in children and adolescents with moderate-to-severe alopecia areata (AA), with the improvement in hair loss sustained through months after treatment discontinuation, according to data from the phase II/III RAAINBOW trial.